Long-term intrathecal baclofen infusion for treatment of spasticity

View More View Less
  • 1 Department of Neurosurgery, Rush Medical College, Chicago, Illinois
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
Print or Print + Online

✓ Seven patients with spasticity of spinal cord origin have been maintained for up to 2 years with continuous spinal intrathecal infusion of baclofen. Prior to treatment, all of the patients had severe rigidity in their lower limbs and most had frequent and extensive spontaneous spasms, all of which greatly interfered with their activities of daily living. Oral antispasmodic medications were ineffective or caused central side effects. The patients underwent implantation of a programmable drug pump connected to a lumbar subarachnoid catheter. Within days of beginning continuous intrathecal baclofen infusion, the muscle tone was reduced to normal levels and spasms were eliminated. Over the ensuing months, muscle tone remained normal, but short-duration spasms could be induced by some activities. The greatest benefits to the patients were improvement in activities of daily living and better sleep due to reduced spasms. The baclofen doses were increased over the first few months but then were stabilized or only increased slightly, with the maximum dose being 650 μg/day. The most serious complications were two drug overdoses which took several days to clear up and were due to malfunctions of an earlier pump model. Baclofen clearance from the cerebrospinal fluid occurs with a half-life of 5 hours. The most serious concern in maintaining patients indefinitely on intrathecal baclofen is whether drug tolerance will eventually occur.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
  • 1.

    Blasberg RG: Methotrexate, cytosine arabinoside, and BCNU concentration in brain after ventriculocisternal perfusion. Cancer Treat Rep 61:625631, 1977 Blasberg RG: Methotrexate, cytosine arabinoside, and BCNU concentration in brain after ventriculocisternal perfusion. Cancer Treat Rep 61:625–631, 1977

    • Search Google Scholar
    • Export Citation
  • 2.

    Bleyer WA, & Dedrick RL: Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep 61:703708, 1977 Bleyer WA, Dedrick RL: Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep 61:703–708, 1977

    • Search Google Scholar
    • Export Citation
  • 3.

    Dralle D, , Müller H, & Zierski J, et al: Intrathecal baclofen for spasticity. Lancet 2:1003, 1985 (Letter) Dralle D, Müller H, Zierski J, et al: Intrathecal baclofen for spasticity. Lancet 2:1003, 1985 (Letter)

    • Search Google Scholar
    • Export Citation
  • 4.

    Erickson DL, , Blacklock JB, & Michaelson M, et al: Control of spasticity by implantable continuous flow morphine pump. Neurosurgery 16:215217, 1985 Erickson DL, Blacklock JB, Michaelson M, et al: Control of spasticity by implantable continuous flow morphine pump. Neurosurgery 16:215–217, 1985

    • Search Google Scholar
    • Export Citation
  • 5.

    Hattab JR: Review of European clinical trials with baclofen, in Feldman RG, , Young RR, & Koella WP (eds): Spasticity: Disordered Motor Control. Miami: Symposia Specialists, 1980, pp 7185 Hattab JR: Review of European clinical trials with baclofen, in Feldman RG, Young RR, Koella WP (eds): Spasticity: Disordered Motor Control. Miami: Symposia Specialists, 1980, pp 71–85

    • Search Google Scholar
    • Export Citation
  • 6.

    Knuttson E, , Lindblom U, & Mårtensson A: Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis. J Neurol Sci 23:473484, 1974 Knuttson E, Lindblom U, Mårtensson A: Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis. J Neurol Sci 23:473–484, 1974

    • Search Google Scholar
    • Export Citation
  • 7.

    Kroin JS, , Penn RD, & Beissinger RL, et al: Reduced spinal reflexes following intrathecal baclofen in the rabbit. Exp Brain Res 54:191194, 1984 Kroin JS, Penn RD, Beissinger RL, et al: Reduced spinal reflexes following intrathecal baclofen in the rabbit. Exp Brain Res 54:191–194, 1984

    • Search Google Scholar
    • Export Citation
  • 8.

    Onofrio BM, , Yaksh TL, & Arnold PG: Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc 56:516520, 1981 Onofrio BM, Yaksh TL, Arnold PG: Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc 56:516–520, 1981

    • Search Google Scholar
    • Export Citation
  • 9.

    Penn RD, & Kroin JS: Continuous intrathecal baclofen for severe spasticity. Lancet 2:125127, 1985 Penn RD, Kroin JS: Continuous intrathecal baclofen for severe spasticity. Lancet 2:125–127, 1985

    • Search Google Scholar
    • Export Citation
  • 10.

    Penn RD, & Kroin JS: Intrathecal baclofen alleviates spinal cord spasticity. Lancet 1:1078, 1984 (Letter) Penn RD, Kroin JS: Intrathecal baclofen alleviates spinal cord spasticity. Lancet 1:1078, 1984 (Letter)

    • Search Google Scholar
    • Export Citation
  • 11.

    Penn RD, , Paice JA, & Gottschalk W, et al: Cancer pain relief using chronic morphine infusion. Early experience with a programmable implanted drug pump. J Neurosurg 61:302306, 1984 Penn RD, Paice JA, Gottschalk W, et al: Cancer pain relief using chronic morphine infusion. Early experience with a programmable implanted drug pump. J Neurosurg 61:302–306, 1984

    • Search Google Scholar
    • Export Citation
  • 12.

    Price GW, , Wilkin GP, & Turnbull MJ, et al: Are baclofensensitive GABAb receptors present on primary afferent terminals of the spinal cord? Nature 307:7174, 1984 Price GW, Wilkin GP, Turnbull MJ, et al: Are baclofensensitive GABAb receptors present on primary afferent terminals of the spinal cord? Nature 307:71–74, 1984

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 766 173 12
Full Text Views 275 25 2
PDF Downloads 147 25 1
EPUB Downloads 0 0 0